Bristol-Myers Squibb Company's Sprycel Wins European Market Approval for Chronic Myeloid Leukemia

Published: Dec 10, 2010

Wall Street Journal -- Bristol-Myers Squibb Co.'s (BMY) cancer drug Sprycel has been given marketing approval in Europe for the treatment of so-called Philadelphia chromosome positive chronic phase chronic myeloid leukemia, or CML. Sprycel, also known by its active ingredient name dasatinib, is the first new treatment to be approved in the European Union with superior efficacy to Novartis AG's (NOVN.VX, NVS) Gleevec in this indication since 2001, the U.S. drug maker said in a statement.

Back to news